MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

NVP-ACC789

CAS No. : 300842-64-2

MCE 站：NVP-ACC789

产品活性：NVP-ACC789 是 人 VEGFR-1，VEGFR-2 (鼠 VEGFR-2)，VEGFR-3 和 PDGFR-β 的抑制剂，IC₅₀ 值分别为 0.38，0.02 (0.23)，0.18 和 1.4 μM。

研究领域：Protein Tyrosine Kinase/RTK

作用靶点：VEGFR  |  PDGFR

In Vitro: The enzymatic kinase assays demonstrate that NVP-ACC789 is an inhibitor of human VEGFR-1, VEGFR-2 (mouse VEGFR-2), VEGFR-3 and PDGFR-β with IC₅₀s of 0.38, 0.02 (0.23), 0.18, 1.4 μM, respectively. In VEGF-treated cultures, addition of the VEGFR-2 inhibitor NVP-ACC789 reduces BME cell number to baseline levels from 1 μM. Likewise, bFGF-induced BME cell proliferation is reduced markedly by NVP-ACC789 from 1 to 10 μM, without however reaching basal levels. NVP-ACC789 is found to be a potent inhibitor of VEGF-induced HUVE cell proliferation with an IC₅₀ of 1.6 nM. NVP-ACC789 also completely inhibits VEGF-induced BME and BAE cell invasion and VEGF-C-induced BAE cell invasion. The inhibition is dose-dependent in both cell types with a maximal effect from 1 μM.

In Vivo: NVP-ACC789 which is given in daily oral doses for 6 days blocks VEGF-induced angiogenesis in a dose-dependent manner. NVP-ACC789 also inhibits the response to bFGF to some extent, but the dose-response curve is not linear for NVP-ACC789.

相关产品：Bioactive Compound Library Plus  |  Kinase Inhibitor Library  |  Protein Tyrosine Kinase Compound Library  |  Anti-Cancer Compound Library  |  Differentiation Inducing Compound Library  |  Reprogramming Compound Library  |  Anti-Breast Cancer Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Anti-Blood Cancer Compound Library  |  Bevacizumab  |  Sunitinib  |  Imatinib  |  Semaxinib  |  SU 5402  |  PD173074  |  5Z-7-Oxozeaenol  |  Cediranib  |  SAR131675  |  Gandotinib  |  GW806742X  |  Tanshinone IIA  |  PF-03814735  |  Vatalanib dihydrochloride  |  CP-547632  |  AST 487  |  Tyrphostin A9  |  Ki20227  |  Motesanib  |  SU14813  |  Ramucirumab  |  SU1498  |  MAZ51  |  PP121  |  PP58  |  Sennoside B  |  Ki8751

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。